SHANGHAI, March 23, 2025 /PRNewswire/ — WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the "Biologics – Global" category. It has also been recognized for excellence in "Best Scientific Expertise", "Best Seamless Delivery Across Phases", "Best Innovative Approach to Technology and Process Execution", making it the most lauded company in the ceremony. This marks WuXi Biologics' eighth consecutive year receiving the CDMO Leadership Award, underscoring its commitment to advancing integrated technology platforms that accelerate biologics discovery, development, and manufacturing. It shortened the development time for monoclonal antibody projects from DNA to Investigational New Drug (IND) application to 9 months, with a recent autoimmune disease project completed in just 6 months.